New Partnership with REGEnLIFE
The director’s board of REGEnLIFE met yesterday in Paris with the Chairman of IGHS Group, Dr. José Alexandre Cunha and the Commercial Counsellor António Sousa to develop a strategic partnership between both companies.
REGEnLIFE is an innovative company based in Montpellier. It is currently developing a new therapeutic approach for the prevention and treatment of neurodegenerative diseases.
An achievable partnership taking into consideration the transversality of the companies that make up the IGHS group.
-
Innov.Cell ended its successful participation in CPHI 2024
Innov.Cell, a subsidiary of IGHS, ended its successful participation in CPHI 2024, which took place in Milan, with a positive outcome. This year, CPHI was attended by more than 62,000 people and around 2,400 exhibitors from 166 countries. Throughout the event, Innov.Cell met with several potential partners, from R&D, investors, and distributors covering more than 50 countries.
Read more -
OIH Introduces Revolutionary Treatment for Keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS)
Oman International Hospital is thrilled to announce the successful introduction of a groundbreaking procedure designed to treat keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS). This innovative treatment marks a significant advancement in ophthalmology, offering new hope to patients suffering from this debilitating corneal disorder.
Read more